Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study - Buch, Maya H; Bhatt, Deepak L; Charles-Schoeman, Christina; Giles, Jon T; Mikuls, Ted; Koch, Gary G; Ytterberg, Steven; Nagy, Edward; Jo, Hyejin; Kwok, Kenneth; Connell, Carol A; Masri, Karim Richard; et al. (Rheumatic & musculoskeletal diseases open, 2024)
Keywords: Antirheumatic Agents; Arthritis, Rheumatoid; Arthritis, Rheumatoid - complications; Arthritis, Rheumatoid - drug therapy; Cardiovascular Diseases; Heart Failure; Humans; Myocardial Infarction - epidemiology; Myocardial Infarction - etiology; Piperidines - adverse effects; Pyrimidines; Rheumatoid arthritis; Skin cancer; Therapeutics; Thromboembolism; TNF inhibitors; Transient ischemic attack; Tumor Necrosis Factor Inhibitors; Venous Thromboembolism; United States--US; Antirheumatic Agents; Tumor Necrosis Factor Inhibitors; Cardiovascular Diseases; Arthritis, Rheumatoid; Therapeutics